← All trials
NCT04650126
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 12, 2021
- Primary completion
- Dec 23, 2021
- Completion date
- Feb 15, 2022
- First posted
- Dec 2, 2020
- Last posted
- Jul 26, 2021
- Enrollment
- 49
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Baliopharm Pty LtdLead sponsor
- Q-PharmOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.